Genedrive (GB:GDR) has released an update.
Genedrive PLC, a leading pharmacogenetic testing company, announced the successful passage of all proposed resolutions at their recent General Meeting, signaling a positive development for the company. Shareholders can anticipate the Admission of Conditional Placing Shares, Open Offer Shares, and the REX Offer Shares to become effective on June 3, 2024, potentially influencing the company’s stock profile. Genedrive continues to innovate in the point of care testing market with its flagship products, which have received NICE recommendations for use in the UK NHS.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.
